Company: Toleranzia AB
Job title: Chief Executive Officer
Charlotte Fribert, CEO of Toleranzia, studied medicine at the Karolinska Institute and at the Pierre and Marie Curie University of Sorbonne in Paris, where she also obtained a PhD in immunology and biotechnology. Before Fribert began working at Toleranzia she worked as Project Director in drug development at AstraZeneca in Gothenburg. Prior to this, she founded, developed and led Epixis SA, a vaccine development company based in Paris, which was successfully sold to VBI Vaccines Inc. in the US. Fribert has thus considerable experience both in Toleranzia’s therapy area and in the effective development of small life science companies.